Advances in Renal Cell Carcinoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 624
Special Issue Editors
Interests: real world analysis; urogenital cancers; sarcoma; head and neck cancers; renal cell carcinoma
Special Issue Information
Dear Colleagues,
Medical treatment of renal cell carcinoma has experienced groundbreaking improvements over the last few decades. Evolving from an unselected immunotherapy with interferons and a type of treatment that only benefits very few patients, a broad range of highly effective therapies are available nowadays, including targeted therapies and immunotherapy. Treatment for this malignancy has demonstrated unparallel improvements in survival for patients who are deemed to be incurable. With the advances in medical treatment, an improved understanding of the diverse biological causes of the diseases and the multimodal care of RCC patients with individualized local and medical treatment sequencings represent the future scientific challenges.
Following these dramatic changes, there is still an urgent need to understand the advantages and characteristics of our current treatment strategies in different settings and populations. Therefore, this Special Issue will highlight all aspects of state-of-the-art therapy, including but not limited to special patient populations, prognostic or predictive markers and real-world application experiences.
We welcome all studies who share our fascination for this topic and help to understand how we can treat patients in the most effective manner possible.
Prof. Dr. Philipp Ivanyi
Dr. Hendrik Eggers
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- renal cell carcinoma
- treatment
- metastatic
- prediction
- medical treatment
- immunotherapy
- multimodal therapy
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
